Jefferies analyst David Katz upgrades Las Vegas Sands (NYSE:LVS) from Hold to Buy.
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Avrobio Inc (NASDAQ: AVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for cystinosis,